Treatment of hypertension in the diabetic patient

Therapy

Volumn 6, Issue 4, 2009, Pages 497-505

  Makaryus, Amgad N ^a   McFarlane, Samy I ^b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Coronary heart disease; Diabetes; Hypertension; Metabolic syndrome; Treatment

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; METFORMIN; PERINDOPRIL; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT;

ALBUMINURIA; ANGIONEUROTIC EDEMA; BEHAVIOR THERAPY; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DRUG CONTRAINDICATION; DRUG TOLERABILITY; EDUCATION PROGRAM; EXERCISE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LOW CALORY DIET; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PHYSICAL ACTIVITY; PROTEINURIA; RENAL PROTECTION; REVIEW; STROKE; SYNCOPE; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; WEIGHT REDUCTION;

EID: 70449580314     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.09.33     Document Type: Review

References (44)

1. Lloyd-Jones D, Adams R, Carnethon M et al.: Heart Disease and Stroke Statistics - 2009 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119, 80-486 (2009). ■This is the most recent update to the heart disease statistics kept by the American Heart Association. It contains helpful information that puts this discussion into perspective.
2. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004).
3. Pinhas-Hamiel O, Zeitler P: The global spread of Type 2 diabetes mellitus in children and adolescents. J. Pediatr. 146(5), 693-700 (2005). (Pubitemid 40616257)
4. Suzuki T, Homma S: Treatment of hypertension and other cardiovascular risk factors in patients with metabolic syndrome. Med. Clin. North Am. 91(6), 1211-1223 (2007). (Pubitemid 47625439)
5. Harris MI, Flegal KM, Cowie CC et al.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21, 518-524 (1998).
6. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet. Med. 15, 539-553 (1998).
7. Chobanian AV, Bakris GL, Black HR et al.: National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289(19), 2560-2571 (2003). ■This is an important guideline statement that underlies many of the treatment algorithms for hypertension.
8. Mancia G, De Backer G, Dominiczak A et al.:; the task force for the management of arterial hypertension of the European Society of Hypertension; the task force for the management of arterial hypertension of the European Society of Cardiology: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28(12), 1462-1536 (2007). ■This is an excellent up-to-date guideline statement on the management of hypertension from the European Society of Cardiology.
9. Malik S, Wong ND, Franklin SS et al.: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110, 1245-1250 (2004). (Pubitemid 39202340)
10. Natali A, Pucci G, Boldrini B, Schillaci G: Metabolic syndrome: at the crossroads of cardiorenal risk. J. Nephrol. 22(1), 29-38 (2009).
11. Mancia G, Bousquet P, Elghozi JL et al.: The sympathetic nervous system and the metabolic syndrome. J. Hypertens. 25(5), 909-920 (2007). (Pubitemid 46573105)
12. Whaley-Connell A, Palmer J, Sowers JR: Risk stratification and treatment options for hypertensive patients with metabolic syndrome and prediabetes. Johns Hopkins Advanced Studies Med. 5(10C), S1011-S1018 (2005).
13. Sacks FM, Svetkey LP, Vollmer WM et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet: DASH-Sodium Collaborative Research Group. N. Engl. J. Med. 344, 3-10 (2001).
14. Look AHEAD Research Group; Pi-Sunyer X, Blackburn G, Brancati FL et al.: Reduction in weight and cardiovascular disease risk factors in individuals with Type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 30(6), 1374-1383 (2007). (Pubitemid 46871141)
15. El-Atat F, Aneja A, Mcfarlane S, Sowers J: Obesity and hypertension. Endocrinol. Metab. Clin. North Am. 32, 823-854 (2003).
16. Hansson L, Zanchetti A, Carruthers SG et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351, 1755-1762 (1998).
17. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265, 3255-3264 (1991).
18. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 288, 2981-2997 (2002). ■This is a landmark trial that assessed the efficacy of the various antihypertensive medications.
19. Israili ZH, Lyoussi B, Hernández- Hernández R, Velasco M: Metabolic syndrome: treatment of hypertensive patients. Am. J. Ther. 14(4), 386-402 (2007). (Pubitemid 47224822)
20. Hansson L, Lindholm LH, Niskanen L et al.: Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 353, 611-616 (1999). (Pubitemid 29087980)
21. Yusuf S, Sleight P, Pogue Bosch J, Davies JR, Dagenais G: Effects of an angiotensinconverting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
22. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253-259 (2000).
23. Khan K, Govindarajan G, Whaley-Connell A, Sowers JR: Diabetic hypertension. Heart Fail. Clin. 2, 25-36 (2006).
24. Sowers JR, Reed J: Clinical advisory treatment of hypertension in diabetes. J. Clin. Hypertens. 2(2),132-133 (2002).
25. Larochelle P, Clack JM, Marbury TC, Sareli P, Kreiger EM, Reeves RA: Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am. J. Cardiol. 80, 1613-1615 (1997). (Pubitemid 28011845)
26. Yusuf S, Teo KK, Pogue J et al. for the ONTARGET investigators: telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008). ■This recent landmark trial demonstrates what researchers and clinicians have been assuming for a while, that angiotensin receptor blockers are equivalent to angiotensin converting enzyme inhibitors, with fewer side effects.
27. Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T: Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol. 6, 12 (2007). (Pubitemid 46629858)
28. Lewis EJ, Hunsicker LG, Clarke WR et al.: Renoprotective effect of the angiotensinreceptor antagonist irbersartan in patients with nephropathy due to Type 2 diabetesand nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
29. Whaley-Connell A, Sowers JR: Hypertension management in Type 2 diabetes and the JNC VII. In: Endocrinology and Metabolism Clinics of North Amercia. Einhorn D, Rosenstock J (Eds.). WB Saunders Company, Philadelphia, PA, USA, 34(1), 63-75 (2005).
30. Patel A, MacMahon S, Chalmers J et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetesmellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370(9590), 829-840 (2007). (Pubitemid 47362321)
31. Pfeffer MA, Swedberg K, Granger CB et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362(9386), 759-766 (2003). (Pubitemid 37093915)
32. Lindholm LH, Ibsen H, Dahlof B et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 1004-1010 (2002). (Pubitemid 34286537)
33. Palaniappan L, Carnethon MR, Wang Y et al.: Insulin Resistance Atherosclerosis Study. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 27(3), 788-793 (2004).
34. Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT: Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J. Hypertens. 24, 1397-1403 (2006). (Pubitemid 43948340)
35. Birkenhager WH, Staessen JA, Gasowski J, de Leeuw PW: Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst-Eur) trial. J. Nephrol. 13(3), 232-237 (2000). (Pubitemid 30449502)
36. Basile J: New therapeutic options in patients prone to hypertension: a focus on direct renin inhibition and aldosterone blockade. Am. J. Med. Sci. 337(6), 438-444 (2009).
37. Rodilla E, Costa JA, Pérez-Lahiguera F, Baldó E, González C, Pascual JM: Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev. Esp. Cardiol. 62(2), 158-166 (2009).
38. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators: Aliskiren combined with losartan in Type 2 diabetesand nephropathy. N. Engl. J. Med. J358(23), 2433-2446 (2008). (Pubitemid 351793017)
39. Van de Laar FA, Lucassen PL, Akkermans RP et al.: a-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst. Rev. 4, CD005061 (2006).
40. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J: RIO-North America Study Group: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295, 761-775 (2006). (Pubitemid 43244304)
41. Nathan DM, Buse JB, Davidson MB et al.; American Diabetes Association; European Association for the Study of Diabetes: Medical management of hyperglycaemia in Type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52(1), 17-30 (2009). ■This is an important algorithm statement that highlights many of the treatment algorithms for Type 2 diabetes mellitus.
42. Nissen SE, Nicholls SJ, Wolski K et al.; STRADIVARIUS Investigators: Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299(13), 1547-1560 (2008).
43. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group: Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes. Lancet 368, 1160-1172 (2006).
44. Cahill K, Ussher M: Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst. Rev. 4, CD005353 (2007). (Pubitemid 351805177)